IMUNON Reports Interim Progression-Free Survival And Overall Survival Data In Phase 1/2 OVATION 2 Study In Advanced Ovarian Cancer
Portfolio Pulse from Benzinga Newsdesk
IMUNON has reported interim progression-free survival and overall survival data in its Phase 1/2 OVATION 2 study in advanced ovarian cancer. The intent-to-treat population showed a 9-month overall survival improvement over the control arm. A subgroup of patients treated with IMNN-001 + PARPi showed a meaningful progression-free survival and overall survival trend compared with the control arm. Continued follow-up is indicated to confirm initial observations.
September 28, 2023 | 12:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IMUNON's Phase 1/2 OVATION 2 study in advanced ovarian cancer showed promising results, with improved survival rates over the control arm. This could potentially boost the company's stock in the short term.
Positive clinical trial results often lead to increased investor confidence, which can drive up a company's stock price. In this case, IMUNON's OVATION 2 study showed improved survival rates in advanced ovarian cancer patients, which is a significant positive development for the company. However, the final impact on the stock will depend on the market's perception of these results and other factors.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100